A Phase 2 interventional study of Reproxalap Ophthalmic Solution (0.25%) and Vehicle Ophthalmic Solution in Dry Eye, sponsored by Aldeyra Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-24.
Sponsored by Aldeyra Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing reproxalap in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. reproxalap · Dry Eye Syndromes.
Among the 11 studies testing reproxalap in Dry Eye Syndromes, this one is the 6th largest by enrollment, is one of 4 that started in 2021, is one of 5 in phase 2, and was the 5th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →None of the 11 studies testing reproxalap in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 6
First in 2017; this study’s year is marked. 4 started in 2021.
This study's enrollment of 158 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 158 across the 11 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Aldeyra Therapeutics, Inc. is the lead sponsor of 35 studies on the registry; 1 is open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 25 (86%) have results posted.
13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 13 finished, 10 (77%) have results posted.
Among the 13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc., this one is the 8th largest by enrollment, is one of 4 that started in 2021, is one of 6 in phase 2, and was the 7th registered.
Aldeyra Therapeutics, Inc.’s Dry Eye Syndromes studies by the year they started, since 2017.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing reproxalap in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Aldeyra Therapeutics, Inc.’s 13 in Dry Eye Syndromes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Reproxalap Ophthalmic Solution (0.25%)
Drug: Vehicle Ophthalmic Solution
Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days.
Vehicle Ophthalmic Solution administered 7 times over two consecutive days.
Conjunctival Redness Assessed Via Digital Photography Over 90 Minutes in the Dry Eye Chamber
Change from baseline comparison of reproxalap to vehicle for conjunctival redness on a 0 to 4 scale ( 0 = normal, 4 = prominent), where a high score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measure for change from baseline included baseline, treatment group, and nominal time point as fixed effects.
Time frame: The efficacy assessment period was assessed during the 90-minute dry eye chamber at Day 2; baseline was Pre-Dose #1 at Day 1.
Subject-reported Ocular Dryness Score (0 - 100 Visual Analogue Scale (VAS))
Change from baseline comparison of reproxalap to vehicle for subject-reported ocular dryness score VAS (0 = no discomfort, 100 = maximal discomfort), where a high score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measure for change from baseline included baseline, treatment group, and nominal time point as fixed effects.
Time frame: The efficacy assessment period was assessed during the 90-minute dry eye chamber at Day 2; baseline was Pre-Dose #1 at Day 1.
Schirmer Test Change From Baseline After the First Dose on Day 1
Change from baseline comparison of reproxalap to vehicle for Schirmer test on a millimeter line (0 = none, 35 = maximum), where a shorter length indicates a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measure for change from baseline included baseline and treatment group as fixed effects.
Time frame: The efficacy assessment period was before and after the final dose on Day 1; baseline was Pre-Dose #1 at Day 1.
| Milestone | Reproxalap (0.25%) | Vehicle |
|---|---|---|
| Started | 80 | 78 |
| Completed | 79 | 75 |
| Not completed | 1 | 3 |
Change from baseline comparison of reproxalap to vehicle for conjunctival redness on a 0 to 4 scale ( 0 = normal, 4 = prominent), where a high score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measure for change from baseline included baseline, treatment group, and nominal time point as fixed effects.
| units on a scale | Reproxalap (0.25%) | Vehicle |
|---|---|---|
| Conjunctival Redness Assessed Via Digital Photography Over 90 Minutes in the Dry Eye Chamber | 0.066 ± 0.0346 | 0.183 ± 0.0353 |
Change from baseline comparison of reproxalap to vehicle for subject-reported ocular dryness score VAS (0 = no discomfort, 100 = maximal discomfort), where a high score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measure for change from baseline included baseline, treatment group, and nominal time point as fixed effects.
| units on a scale | Reproxalap (0.25%) | Vehicle |
|---|---|---|
| Subject-reported Ocular Dryness Score (0 - 100 Visual Analogue Scale (VAS)) | -5.7 ± 2.44 | -3.8 ± 2.51 |
Change from baseline comparison of reproxalap to vehicle for Schirmer test on a millimeter line (0 = none, 35 = maximum), where a shorter length indicates a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measure for change from baseline included baseline and treatment group as fixed effects.
| length in millimeters | Reproxalap (0.25%) | Vehicle |
|---|---|---|
| Schirmer Test Change From Baseline After the First Dose on Day 1 | 4.2 ± 0.83 | 2.1 ± 0.84 |
Collected over The period of time over which adverse events were collected for each subject in the clinical trial was approximately one week.. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Reproxalap (0.25%) | 0/79 (0%) | 0/79 (0%) | 52/79 (65.8%) |
| Vehicle | 0/77 (0%) | 0/77 (0%) | 3/77 (3.9%) |
| Event | Reproxalap (0.25%) | Vehicle |
|---|---|---|
| General disorders and administration site conditionsGeneral disorders | 52/79 | 3/77 |
Intent-to-treat population
| Age, Categorical(Participants) | Reproxalap (0.25%) | Vehicle | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 43 | 48 | 91 |
| >=65 years | 37 | 30 | 67 |
| Sex: Female, Male(Participants) | Reproxalap (0.25%) | Vehicle | Total |
|---|---|---|---|
| Female | 59 | 55 | 114 |
| Male | 21 | 23 | 44 |
| Ethnicity (NIH/OMB)(Participants) | Reproxalap (0.25%) | Vehicle | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 11 | 16 |
| Not Hispanic or Latino | 75 | 67 | 142 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Reproxalap (0.25%) | Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 2 | 3 | 5 |
| Black or African American | 8 | 3 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| White | 67 | 68 | 135 |
| Other | 0 | 1 | 1 |
| Multiple | 2 | 1 | 3 |
| Region of Enrollment(participants) | Reproxalap (0.25%) | Vehicle | Total |
|---|---|---|---|
| United States | 80 | 78 | 158 |
| Iris Color (Right Eye)(Participants) | Reproxalap (0.25%) | Vehicle | Total |
|---|---|---|---|
| Black | 0 | 0 | 0 |
| Blue | 18 | 18 | 36 |
| Brown | 44 | 31 | 75 |
| Hazel | 7 | 17 | 24 |
| Green | 11 | 12 | 23 |
| Gray | 0 | 0 | 0 |
| Other | 0 | 0 | 0 |
| Iris Color (Left Eye)(Participants) | Reproxalap (0.25%) | Vehicle | Total |
|---|---|---|---|
| Black | 0 | 0 | 0 |
| Blue | 18 | 18 | 36 |
| Brown | 44 | 31 | 75 |
| Hazel | 7 | 17 | 24 |
| Green | 11 | 12 | 23 |
| Gray | 0 | 0 | 0 |
| Other | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2021 to primary completion in Sep 2021, 2 months.
Results were first posted in Mar 2023, 1 year 5 months after primary completion.
Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 2 months is below that.
Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Reproxalap